BTK and myeloid sarcoma: Thereby, this study provides vital pre-clinical data that will likely support the prospective findings from ongoing or future clinical trials investigating therapeutic BTK inhibition by evobrutinib and other small molecule BTK inhibitors for the treatment of mechanisms driving MS disease progression.